![]() |
|
|
Vol. 283, Issue 2, 494-500, 1997
Department of Pharmacology, Cornell University Medical College, New
York, New York
During protracted myocardial ischemia, ATP depletion promotes
Na+ accumulation in sympathetic terminals and prevents
vesicular storage of norepinephrine (NE). This forces the reversal of
the neuronal uptake1 transporter, and NE is massively
released (carrier-mediated release). We had shown that histamine
H3 receptors (H3Rs) modulate ischemic NE
release in animals. We have now used a human model of protracted
myocardial ischemia to investigate whether H3Rs may control
carrier-mediated NE release. Surgical specimens of human atrium were
incubated in anoxic conditions. NE release increased ~7-fold within
70 min of anoxia. This release was carrier mediated because it was
Ca++ independent and inhibited by the uptake1
inhibitor desipramine. Furthermore, the Na+/H+
exchanger (NHE) inhibitors ethyl-isopropyl-amiloride and HOE 642, and
the Na+ channel blocker tetrodotoxin inhibited NE release,
whereas the Na+ channel activator aconitine potentiated it.
The selective H3R agonist imetit decreased NE release, an
effect that was blocked by each of the H3R antagonists
thioperamide and clobenpropit. Notably, imetit acted synergistically
with ethyl-isopropyl-amiloride, HOE 642 and tetrodotoxin to reduce
anoxic NE release. Thus, activation of H3R appears to
result in an inhibition of both NHE- and voltage-dependent Na+ channels. Most importantly, endogenous histamine was
released from the anoxic human heart, and thioperamide and clobenpropit each alone increased NE release, indicating that H3R become
activated in myocardial ischemia. Our findings indicate that
H3Rs are likely to mitigate sympathetic overactivity in the
ischemic human heart and suggest new therapeutic strategies to
alleviate dysfunctions associated with myocardial ischemia.
This article has been cited by other articles:
![]() |
U. Schaefer, T. Machida, S. Vorlova, S. Strickland, and R. Levi The plasminogen activator system modulates sympathetic nerve function J. Exp. Med., September 4, 2006; 203(9): 2191 - 2200. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yamamoto, N. Matsumoto, M. Kanazawa, M. Fujita, M. Takaoka, C. E. Gariepy, M. Yanagisawa, and Y. Matsumura Different Contributions of Endothelin-A and Endothelin-B Receptors in Postischemic Cardiac Dysfunction and Norepinephrine Overflow in Rat Hearts Circulation, January 25, 2005; 111(3): 302 - 309. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Koyama, N. Seyedi, W.-P. Fung-Leung, T. W. Lovenberg, and R. Levi Norepinephrine Release from the Ischemic Heart Is Greatly Enhanced in Mice Lacking Histamine H3 Receptors Mol. Pharmacol., February 1, 2003; 63(2): 378 - 382. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Seyedi, M. Koyama, C. J. Mackins, and R. Levi Ischemia Promotes Renin Activation and Angiotensin Formation in Sympathetic Nerve Terminals Isolated from the Human Heart: Contribution to Carrier-Mediated Norepinephrine Release J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 539 - 544. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Boehm and H. Kubista Fine Tuning of Sympathetic Transmitter Release via Ionotropic and Metabotropic Presynaptic Receptors Pharmacol. Rev., March 1, 2002; 54(1): 43 - 99. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yamasaki, I. Tamai, and Y. Matsumura Activation of histamine H3 receptors inhibits renal noradrenergic neurotransmission in anesthetized dogs Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2001; 280(5): R1450 - R1456. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Silver, C. J. Mackins, N. C. E. Smith, I. L. Koritchneva, K. Lefkowitz, T. W. Lovenberg, and R. Levi Coupling of histamine H3 receptors to neuronal Na+/H+ exchange: A novel protective mechanism in myocardial ischemia PNAS, February 15, 2001; (2001) 51599198. [Abstract] [Full Text] |
||||
![]() |
R. Maruyama, E. Hatta, K. Yasuda, N. C. E. Smith, and R. Levi Angiotensin-Converting Enzyme-Independent Angiotensin Formation in a Human Model of Myocardial Ischemia: Modulation of Norepinephrine Release by Angiotensin Type 1 and Angiotensin Type 2 Receptors J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 248 - 254. [Abstract] [Full Text] |
||||
![]() |
R. Levi and N. C. E. Smith Histamine H3-Receptors: A New Frontier in Myocardial Ischemia J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 825 - 830. [Abstract] [Full Text] |
||||
![]() |
N. C. E. Smith and R. Levi LLC-PK1 Cells Stably Expressing the Human Norepinephrine Transporter: A Functional Model of Carrier-Mediated Norepinephrine Release in Protracted Myocardial Ischemia J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 456 - 463. [Abstract] [Full Text] |
||||
![]() |
E. Hatta, R. Maruyama, S. J. Marshall, M. Imamura, and R. Levi Bradykinin Promotes Ischemic Norepinephrine Release in Guinea Pig and Human Hearts J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 919 - 927. [Abstract] [Full Text] |
||||
![]() |
R. B. Silver, C. J. Mackins, N. C. E. Smith, I. L. Koritchneva, K. Lefkowitz, T. W. Lovenberg, and R. Levi Coupling of histamine H3 receptors to neuronal Na+/H+ exchange: A novel protective mechanism in myocardial ischemia PNAS, February 27, 2001; 98(5): 2855 - 2859. [Abstract] [Full Text] [PDF] |
||||